-
Mashup Score: 0
Avapritinib demonstrated encouraging clinical activity in Chinese patients with PDGFRA D842V–mutant gastrointestinal stromal in a bridging study of the NAVIGATOR trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Lenvatinib Treatment Can Continue in Unresectable HCC With Child–Pugh Class-B Liver Function - 3 year(s) ago
Lenvatinib can continue to be administered in patients with unresectable hepatocellular carcinoma that has Child-Pugh class B liver function, as they experienced a similar tumor size reduction as their Child-Pugh class A counterparts in a post-hoc analysis of the phase 3 REFLECT trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Lenvatinib can continue to be given to patients with unresectable HCC that has CP-B liver function, as they experienced a similar tumor size reduction as their CP-A counterparts in a post-hoc analysis of the phase 3 REFLECT trial. @myESMO #WorldGI2021 https://t.co/y7tErUf6VT
-
-
Mashup Score: 0Tislelizumab, TTF Studies Poised to Address HCC Questions - 3 year(s) ago
The optimal sequence of therapies in the second- or later-line settings for patients with hepatocellular carcinoma remains unclear.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The optimal sequence of therapies in the second- or later-line settings for patients with hepatocellular carcinoma remains unclear. @myESMO #WorldGI2021 #hpbcsm https://t.co/yNBssgKSKc
-
-
Mashup Score: 0GSK2636771/Paclitaxel Combo Demonstrates Early Promise in Advanced PTEN-Deficient Gastric Cancer - 3 year(s) ago
The novel PI3Kß inhibitor GSK2636771 plus paclitaxel led to encouraging clinical activity as well as a tolerable safety profile in patients with PTEN-deficient advanced gastric cancer who progressed following frontline chemotherapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The novel PI3Kß inhibitor GSK2636771 plus paclitaxel led to encouraging clinical activity & a tolerable safety profile in patients w/ PTEN-deficient advanced gastric cancer who progressed following frontline chemotherapy. @myESMO #WorldGI2021 #esocsm https://t.co/ZXHH3K7C7E
-
-
Mashup Score: 0Urologic Care Rates Decline Across US Demographics During Height of COVID-19 Pandemic - 3 year(s) ago
The provision of urologic care underwent a significant decline during the height of the COVID-19 pandemic across all demographic groups and practice settings in the United States, regardless of the timing of stay-at-home order mandates.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Urologic Care Rates Decline Across US Demographics During Height of COVID-19 Pandemic @PennMedicine @myESMO #WorldGI2021 #COVID19 https://t.co/WlMQXGVsce
-
-
Mashup Score: 0Pembrolizumab/Lenvatinib Regimen Being Tested in Advanced Gastroesophageal Adenocarcinoma - 3 year(s) ago
Frontline pembrolizumab plus lenvatinib, and chemotherapy is being tested against chemotherapy alone in patients with advanced gastroesophageal adenocarcinoma, as part of the international, 2-part, phase 3 LEAP-015 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
LEAP-015 will examine the safety of pembrolizumab/lenvatinib, along with PFS and OS achieved with the combination therapy vs standard-of-care chemotherapy in gastroesophageal adenocarcinoma. @myESMO #WorldGI2021 #esocsm https://t.co/3Ynw6oAKEI https://t.co/Dd5LDsNCW8
-
-
Mashup Score: 1ESMO World Congress on Gastrointestinal Cancer 2021 - 3 year(s) ago
Ghassan K Abou-Alfa (Memorial Sloan Kettering Cancer Center, New York, NY, USA) presented the results of a global phase 2 study of the investigational PD-1 antibody tislelizumab in patients with previously treated unresectable hepatocellular carcinoma. 249 patients were enrolled and received tislelizumab 200 mg intravenously every 3 weeks. The primary endpoint, overall response rate by…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
News: Read our Editor’s highlights from #ESMO World Congress on Gastrointestinal Cancer 2021 #WorldGI2021 @myESMO https://t.co/RDXoS0ZqKM
-
-
Mashup Score: 0
Avapritinib demonstrated encouraging clinical activity in Chinese patients with PDGFRA D842V–mutant gastrointestinal stromal in a bridging study of the NAVIGATOR trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Avapritinib Elicits Clinical Activity in Chinese Patients With PDGFRA D842V+ GIST @myESMO #WorldGI2021 https://t.co/cDEHX7g86J
-
-
Mashup Score: 1Tislelizumab Benefit in HCC Undimmed by Prior Therapies - 3 year(s) ago
Patients with advanced hepatocellular carcinoma (HCC) can achieve durable responses, and overall survival is “encouraging” with the novel immunotherapy, even after multiple prior therapies.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
With the new immunotherapy tislelizumab, durable responses are achieved for patients with advanced HCC, regardless of the number of prior lines of therapy, show results from a phase 2, open-label trial. https://t.co/1EaEujRbMs #WorldGI2021
-
-
Mashup Score: 0Tislelizumab, TTF Studies Poised to Address HCC Questions - 3 year(s) ago
The optimal sequence of therapies in the second- or later-line settings for patients with hepatocellular carcinoma remains unclear.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tislelizumab, TTF Studies Poised to Address HCC Questions @myESMO #WorldGI2021 #hpbcsm https://t.co/rJngnVgLDq
-
Avapritinib had moderate clinical activity in the third and later-line treatment of a Chinese patient with GIST, making it the potential new treatment option for the population. @myESMO #WorldGI2021 https://t.co/Z0O0500BCg https://t.co/COZS1E5aff